The Pall eBDS System is a highly sensitive culture-based test that detects bacterial contamination of red blood cells, reducing the risk of sepsis and death from transfusion. The system's novel approach to detection measures oxygen consumption as a marker for bacteria, allowing for effective detection of commonly found contaminants.
A new technology developed by Pall Corporation enables faster and more efficient cell harvesting for cell therapy, with processing times reduced to under 15 minutes. The system exhibits higher yield of cells and is easy to use, adhering to Good Manufacturing Practice (cGMP) regulations.
Pall Corporation's total process management approach can improve vaccine production economics by reducing time, safety risks, and expenses. The use of scalable and disposable technologies enables efficient processing of larger volumes, addressing the need for increased manufacturing capacity in response to pandemic threats.
Prestoraged pooled platelets have been shown to have an equivalent clinical response and quality to platelets pooled at the time of transfusion, increasing platelet availability and reducing hospital costs. The Pall eBDS System has demonstrated high sensitivity in detecting bacteria in pooled platelets.
A new study found that red blood cells filtered through the Pall Leukotrap Affinity Prion Reduction Filter System retain their therapeutic value and quality after 42 days of storage, exceeding FDA requirements. The filter demonstrated a 99.9% reduction of prions, including sporadic CJD, scrapie, and mouse-adapted human vCJD.
A new study confirms the filter's effectiveness in reducing prions by up to 99.9%, providing a critical safety measure against vCJD transmission through blood transfusion. The technology has the potential to safeguard the global blood supply and prevent future outbreaks.
Tap water is a significant source of hospital-acquired infections, with biofilm harbouring pathogenic microorganisms. Point-of-use 0.2 micron filters can significantly reduce the release of pathogens and aerosols, providing an absolute barrier between patients and contaminated water.
The Pall Leukotrap Affinity Prion Reduction Filter reduces leukocytes and prions by 99%, making it effective against vCJD. The filter also preserves red cells without compromising their efficacy or purity.
A study found that the Pall Leukotrap Affinity Prion Reduction Filter reduces infectious vCJD prions in red blood cell concentrates below detection limits. The filter also reduced scrapie prions, a similar TSE, from blood, with no clinical symptoms reported in animals treated with filtered blood.
Experts warn of a potential second wave of vCJD infections due to increased cases in France and the UK. The panel discussion highlighted the need for enhanced safety measures to prevent human-to-human transmission of this fatal neurodegenerative disease.